AX-0076 / Axceso Biopharma - LARVOL DELTA

Axceso Biopharma advances S1PR1 agonist platform for IBD, sepsis, ARDS (Chosun Biz) - "Bio venture Axceso Biopharma said on the 12th that it will develop the drug candidate '3,4-cPP (AX-0076)' as a platform-type candidate that can be applied to multiple indications, including inflammatory bowel disease, sepsis, and acute respiratory distress syndrome (ARDS)...The company is first looking at inflammatory bowel disease (IBD) as a development indication. It said improvements in disease activity and tissue damage markers were observed in animal models, and improved survival was also confirmed in a sepsis animal model...Axceso Biopharma also presented the possibility of developing an oral formulation. According to the company, oral bioavailability is about 20.6% to 29.5% based on mouse pharmacokinetic studies."

New molecule • Preclinical • Acute Respiratory Distress Syndrome • Inflammatory Bowel Disease